Phase 2 Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma Clinical Trials
7 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–7 of 7 trials
Recruiting
Phase 2
A Comprehensive Multiomic Biomarker Evaluation Across Two Single-arm Cohorts to Elucidate Mechanisms of Response and Resistance in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC)
Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma
University Health Network, Toronto30 enrolled1 locationNCT07408063
Recruiting
Phase 2
Study of Cetuximab Plus/Minus Weekly Paclitaxel After Progression To First-Line Pembrolizumab Plus Platinum-5FU in Subjects With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck.
Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello65 enrolled11 locationsNCT06856213
Recruiting
Phase 2
Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCC
Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University39 enrolled1 locationNCT07088211
Recruiting
Phase 2
Iparomlimab and Tuvonralimab in HNSCC
Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University30 enrolled1 locationNCT07090317
Recruiting
Phase 1Phase 2
A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer
Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma
Suzhou Suncadia Biopharmaceuticals Co., Ltd.96 enrolled2 locationsNCT07059221
Recruiting
Phase 2
Dalpicilib Plus Cetuximab Compared With Cetuximab Alone in HPV-negative, Anti-PD-1-resistant R/M HNSCC
Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University98 enrolled1 locationNCT06935188
Recruiting
Phase 2
A Study of Pembrolizumab (MK-3475) Plus Platinum and Gemcitabine as First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (PIPER)
Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma
University of Malaya63 enrolled1 locationNCT05286619